Kidney Transplantation clinical trials
Showing 51–70 of 70 active trials. Describe your situation to see which ones you may be eligible for.
- (TNX-1500) in Kidney Transplant Recipients
- AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function
- Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
- Antibiotics for Kidney Transplant Recipients
- Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function
- Phenotype Guided Vasoactive Medication During Kidney Transplantation
- Letermovir for R+ Study
- MRI Technical Development and Applications in Kidney Disease
- Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
- Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
- Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
- System Interventions to Achieve Early and Equitable Transplants Study - Long-Term
- Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
- MITIGAAT: Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
- Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- Predicting Mortality in Kidney Transplant Recipients
- APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.